VELATAN EYE DROPS

Latanoprost 50 micrograms/mL (0.005% w/v)
Sterile ophthalmic solution | Pack size: 2.5 mL

COMPOSITION

Each 1 mL contains Latanoprost 50 micrograms (0.05 mg), equivalent to 0.005% w/v. A 2.5 mL fill contains 125 micrograms latanoprost. Other ingredients and preservative, if any: according to the approved Velatan formulation.

THERAPEUTIC CLASS

Prostaglandin F2-alpha analogue; ocular hypotensive and antiglaucoma agent. Primary medical segment: Ophthalmology.

PHARMACOLOGY

Latanoprost is a prostaglandin F2-alpha analogue prodrug that increases aqueous humour outflow, predominantly through the uveoscleral pathway, reducing intraocular pressure (IOP). IOP reduction begins within approximately 3–4 hours and peaks after 8–12 hours.

INDICATIONS

Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, in accordance with locally approved indications.

DOSAGE AND ADMINISTRATION

Instil **one drop in the affected eye(s) once daily in the evening**. Do not use more than once daily; more frequent dosing may reduce the IOP-lowering effect. If a dose is missed, continue with the next scheduled dose without doubling.

METHOD OF USE

Wash hands. Tilt head back, pull down the lower eyelid and instil one drop without touching the dropper tip to the eye, fingers or other surfaces. Close the eye gently and apply light pressure at the inner corner for about one minute. Replace the cap promptly. Use only in the eye; do not inject or swallow.

CONTACT LENSES AND OTHER EYE DROPS

If Velatan contains benzalkonium chloride, remove contact lenses before use and wait at least 15 minutes before reinsertion. Separate other topical ophthalmic medicines by at least 5 minutes. Do not combine with another prostaglandin analogue unless specifically directed by an ophthalmologist.

CONTRAINDICATIONS

Known hypersensitivity to latanoprost or any formulation component, including preservative where present.

WARNINGS: PIGMENTATION

Latanoprost may gradually increase brown pigmentation of the iris, eyelid skin and eyelashes. Iris colour change may be permanent and can produce a difference between treated and untreated eyes. Explain this possibility before starting treatment.

EYELASH CHANGES

Eyelashes may become longer, thicker, darker, more numerous or grow in an altered direction. Changes are usually reversible after discontinuation, but may cause cosmetic asymmetry.

OTHER WARNINGS AND PRECAUTIONS

Use caution in patients with active intraocular inflammation, a history of uveitis or iritis, aphakia or pseudophakia with a torn posterior lens capsule, or other risk factors for macular oedema. Latanoprost may reactivate herpetic keratitis; avoid use in active herpes simplex keratitis unless a specialist advises otherwise.

INFECTION AND CONTAMINATION

Avoid touching the bottle tip. Contaminated ophthalmic solutions can cause serious bacterial keratitis. Seek urgent ophthalmic assessment for severe pain, marked redness, discharge, sudden vision change or suspected contamination.

DRUG INTERACTIONS

In vitro precipitation has occurred when latanoprost is mixed with thimerosal-containing eye drops. Separate topical preparations by at least 5 minutes. Concomitant use of two or more prostaglandin analogues is not recommended.

PREGNANCY AND LACTATION

Use during pregnancy only when the anticipated benefit justifies potential risk. Human breastfeeding data are limited; consider the clinical need and possible infant effects. Seek medical advice before use.

PAEDIATRIC AND ELDERLY USE

Paediatric use should follow locally approved age restrictions and specialist assessment. No routine dose adjustment is generally required solely because of older age.

ADVERSE REACTIONS

Common effects include conjunctival redness, stinging or burning, eye irritation, itching, blurred vision, foreign-body sensation, eyelash changes and increased iris pigmentation. Less common but important effects include keratitis, uveitis and macular oedema. Report persistent or severe symptoms.

OVERDOSAGE

Excessive ocular dosing may cause irritation or redness. If accidentally swallowed, seek medical advice, particularly for children. Management is supportive.

STORAGE

Reference preserved latanoprost products are protected from light and stored unopened at 2–8°C; some permit storage after opening at up to 25°C for 6 weeks. **Follow Velatan-specific validated and approved storage and in-use conditions**; these may differ by formulation and packaging. Do not freeze unless the approved label explicitly permits it.

PRESENTATION

Velatan Eye Drops, Latanoprost 50 micrograms/mL (0.005% w/v): 2.5 mL sterile ophthalmic solution.

MANUFACTURED BY

Vega Pharmaceuticals (Pvt.) Ltd.